CG Oncology, Inc. (CGON)
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
CG Oncology Inc.
No splits on record
Nothing in CGON's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Revenue | $4.04M | $1.14M | $204K | $191K | $10.36M |
| YoY Growth | 254.7% | 458.3% | 6.8% | -98.2% | - |
| Cost of Revenue | $4.65M | $82.1M | $45.75M | $15K | $10K |
| Gross Profit | -$607K | -$80.96M | -$45.55M | $176K | $10.35M |
| Gross Margin | -15.0% | -7108.3% | -22327.5% | 92.1% | 99.9% |
| Research and Development | $116.64M | $82.1M | $45.75M | $29.03M | $18.32M |
| Selling, General, and Administrative | $73.53M | $33.7M | $9.9M | $6.39M | $4.63M |
| Other | $0 | -$82.1M | -$45.75M | $0 | $0 |
| Total Operating Expenses | $190.17M | $33.7M | $9.9M | $35.42M | $22.95M |
| Operating Income (EBIT) | -$190.77M | -$114.67M | -$55.45M | -$35.25M | -$12.61M |
| Operating Margin | -4722.1% | -10067.3% | -27180.9% | -18453.4% | -121.7% |
| Interest Expense | $0 | $0 | $0 | $1K | $451K |
| Interest Income | $29.93M | $26.62M | $6.9M | $0 | $0 |
| Other Income (Expense) | $29.78M | $26.63M | $6.84M | -$197K | -$233K |
| Income Before Tax (EBT) | -$161M | -$88.04M | -$48.61M | -$35.44M | -$12.84M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$161M | -$88.04M | -$48.61M | -$35.44M | -$12.84M |
| Net Income Margin | -3985.0% | -7729.5% | -23827.0% | -18556.5% | -124.0% |
| Supplementary Data | |||||
| EPS | -2.08 | -1.41 | -1.02 | -0.66 | -0.28 |
| Diluted EPS | -2.08 | -1.41 | -1.02 | -0.66 | -0.28 |
| Weighted Average OS | 77.30M | 62.50M | 66.64M | 66.64M | 66.64M |
| EBITDA | -$159.55M | -$88.01M | -$48.59M | -$35.43M | -$12.38M |
| EBITDA Margin | -3949.3% | -7726.7% | -23818.6% | -18548.2% | -119.5% |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Assets | |||||
| Current Assets | |||||
| Cash and Cash Equivalents | $32.49M | $257.07M | $8.27M | $88.14M | $53.61M |
| Short-Term Investments | $709.66M | $484.93M | $179.41M | $55.34M | $0 |
| Cash and Short-Term Investments | $742.15M | $742M | $187.67M | $143.48M | $53.61M |
| Accounts Receivable | $688K | $781K | $92K | $303K | $2K |
| Inventory | $1.56M | $0 | $0 | $0 | $0 |
| Other Current Assets | $15.07M | $11.43M | $6.36M | $3.42M | $4.8M |
| Total Current Assets | $759.48M | $754.21M | $194.12M | $147.21M | $58.41M |
| Long-Term Assets | |||||
| Property, Plant & Equipment Net | $19.57M | $493K | $491K | $506K | $200K |
| Goodwill | $10.3M | $0 | $0 | $0 | $0 |
| Intangible Assets | $575K | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $1.68M | $94K | $4.69M | $33K | $85K |
| Total Long-Term Assets | $32.12M | $587K | $5.18M | $539K | $285K |
| Other Assets | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $791.59M | $754.8M | $199.3M | $147.75M | $58.69M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | $5.71M | $6.52M | $3.24M | $985K | $1M |
| Short-Term Debt | $0 | $0 | $569K | $8.97M | $2.94M |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $286K | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $9.02M | $436K | $547K | $173K | $1.13M |
| Total Current Liabilities | $30.84M | $21.37M | $14.25M | $15.43M | $5.97M |
| Long-Term Liabilities | |||||
| Long-Term Debt | $3M | $0 | $0 | $6.53M | $12.06M |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $307K | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $1.74M | $0 | $13K | $352K | $351K |
| Total Long-Term Liabilities | $8.15M | $52K | $257K | $7.14M | $12.46M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $38.99M | $21.42M | $14.51M | $22.57M | $18.44M |
| Stockholders' Equity | |||||
| Preferred Stock | $0 | $0 | $307.89M | $202.87M | $82.87M |
| Common Stock | $8K | $8K | $0 | $0 | $3K |
| Retained Earnings | -$378.98M | -$217.98M | -$129.94M | -$81.33M | -$45.89M |
| Comprehensive Income & Other | $0 | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $1.13B | $951.35M | $314.73M | $206.51M | $86.14M |
| Total Equity | $752.6M | $733.38M | $184.79M | $125.18M | $40.25M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $791.59M | $754.8M | $199.3M | $147.75M | $58.69M |
| Supplementary Data | |||||
| Total Debt | $7.02M | $238K | $1.03M | $15.94M | $15.13M |
| Net Debt | -$25.47M | -$256.83M | -$7.24M | -$72.2M | -$38.48M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Operating Activities | |||||
| Net Income | -$161M | -$88.04M | -$48.61M | -$35.44M | -$12.84M |
| Depreciation & Amortization | $1.45M | $32K | $17K | $15K | $10K |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $26.68M | $11.4M | $1.53M | $676K | $1.11M |
| Changes in Working Capital: | |||||
| Accounts Receivable | -$320K | -$689K | $0 | $0 | $0 |
| Inventory | -$444K | $0 | $0 | $0 | $0 |
| Accounts Payable | -$1.64M | $3.27M | $2.01M | -$18K | $578K |
| Other Working Capital | $4.68M | $320K | $1.43M | $4.46M | -$2.54M |
| Total Working Capital Change | $2.28M | $2.91M | $3.44M | $4.44M | -$1.97M |
| Other Non-Cash Items | -$1.75M | -$5.01M | -$2.06M | $509K | $30K |
| Net Cash from Operating | -$132.35M | -$78.71M | -$45.68M | -$29.8M | -$13.65M |
| Investing Activities | |||||
| Capital Expenditures | -$134K | -$234K | $0 | -$14K | -$97K |
| Acquisitions | -$21.97M | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$1.07B | -$1.05B | -$517.61M | -$55.34M | $0 |
| Sales of Investments | $844.14M | $745.41M | $396.42M | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$245.82M | -$300.76M | -$121.19M | -$55.35M | -$97K |
| Financing Activities | |||||
| Debt Repaid | - | $365K | $16.29M | - | -$15.2M |
| Common Stock Issuance | $153.59M | $629.47M | $2.08M | $166K | $245K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | -$825K | -$3.42M | $0 | $0 |
| Net Cash from Financing | $153.59M | $628.28M | $87M | $119.69M | $15.45M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$224.58M | $248.8M | -$79.88M | $34.54M | $1.7M |
| Supplementary Data | |||||
| Operating Cash Flow | -$132.35M | -$78.71M | -$45.68M | -$29.8M | -$13.65M |
| Capital Expenditure | -$134K | -$234K | $0 | -$14K | -$97K |
| Free Cash Flow | -$132.48M | -$78.95M | -$45.68M | -$29.82M | -$13.75M |
| Cash at Beginning | $257.07M | $8.27M | $88.14M | $53.61M | $51.91M |
| Cash at End | $32.49M | $257.07M | $8.27M | $88.14M | $53.61M |